Broadcom Inc (AVGO) Stock Price Today
Aura AI Summary
Key Stats
- $1.76TMarket Cap
- -Volume
- TechnologySector
- $481.5752W High
- $278.5952W Low
- -Typical Hold Time
- $1.81TEnterprise Value
- 0.7%Div Yield
- -Trading Activity
Track Broadcom Inc (AVGO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Broadcom Inc has traded between a low of $278.59 and a high of $481.57, highlighting its annual price range. Buy and sell Broadcom Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Most Recent News
US chip stocks fall on fears over new Chinese Kimi K3 model, despite strong earnings from TSMC and ASML.
US semiconductor stocks dropped sharply after the introduction of a new Chinese chip model called Kimi K3, which rattled investors despite strong earnings and raised guidance from major players like TSMC and ASML. The SOXX ETF fell 1.5%, reflecting b...
S&P 500 falls 1.6% as investors shift from growth to value amid inflation and geopolitical concerns
Last week, the S&P 500 dropped 1.6% as investors moved away from large-cap growth stocks toward value and defensive sectors. Energy and commodities outperformed, while technology and momentum stocks lagged due to renewed geopolitical tensions and inf...
Medicus Pharma's redesigned Teverelix study gets FDA and IRB approval, cutting costs and patient numbers significantly.
Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.